

Figure S1. Clinical significance of PODNL1 expression between IDH wildtype (IDH-Wt) and mutant (IDH-Mu) group. **A**, Comparison of PODNL1 expression between IDH-Wt and IDH-Mu groups. **B**, High PODNL1 expression predicted shorter overall survival in both IDH-Wt and IDH-Mu groups. **C**, The PODNL1 expression showed a significant difference between PODNL1 high and low groups in **Supplementary Figure 1B**. (* $P < 0.05$, *** $P < 0.001$)




Figure S2. PODNL1 mRNA expression evaluated by qRT-PCR. A, The PODNL1 expression of the U87 cell line transfected with NC and three PODNL1 targeting shRNAs. **B,** The PODNL1 expression of U251 cell line transfected with PB-C and PB-OE. (** $P < 0.01$, *** $P < 0.001$)




Figure S3. PODNL1 overexpression did not induce the apoptotic change in U251 glioma cells. A, Representative images indicating apoptosis rate between PB-C and PB-OE groups. **B,** Statistical graph suggested no significant difference (n.s.) between PB-C and PB-OE groups.





Figure S4. PODNL1 promoted glioma progression via PI3K/Akt pathway. A, The activation status of PI3K/Akt signaling determined by Western blot. **B,** Representative images from colony formation and Transwell assays.